Vonoprazan is a novel first-in-class potassium-competitive acid blocker (P-CAB) that offers rapid and sustained suppression of gastric acid secretion, representing a significant advancement over traditional proton pump inhibitors (PPIs). It is widely used in pharmaceutical research and clinical practice for the management of acid-related disorders, appealing to patients who require faster symptom relief and more consistent acid control, particularly those with refractory gastroesophageal reflux disease (GERD) or who exhibit poor response to PPIs.
Sarafloxacin is a synthetic, third-generation fluoroquinolone antibiotic developed primarily for veterinary and microbiological research use, exhibiting potent broad-spectrum bactericidal activity against Gram-negative and selected Gram-positive pathogens. It is a key reference standard in antimicrobial residue analysis, veterinary pharmaceutical development, and in vitro susceptibility testing for food-animal and aquaculture pathogens.
Niraparib is a highly selective, potent oral PARP inhibitor used primarily in oncology to treat various forms of cancer, particularly ovarian and prostate cancers with BRCA mutations. It is designed as a targeted therapy to exploit DNA repair deficiencies in tumor cells, offering high efficacy with manageable side effects for patients requiring maintenance treatment after chemotherapy or as a monotherapy in recurrent settings. The product is available in high purity suitable for both pharmaceutical research and clinical development purposes.
Calcitonin, porcine is a highly purified, 32-amino acid polypeptide hormone naturally synthesized by the thyroid C-cells of pigs, supplied as a sterile lyophilized white powder for advanced endocrinological and osteological research. Structurally characterized by a disulfide bridge between Cys1 and Cys7 and a C-terminal proline amide, this peptide shares high sequence homology with human calcitonin, making it a vital tool for scientists studying calcium homeostasis, bone metabolism, and G-protein-coupled receptor (GPCR) signaling. Its well-defined conformation and specific biological activity make it an essential reference standard for pharmaceutical R&D, biochemical laboratories, and academic institutions focused on antiresorptive drug discovery, hypercalcemia mechanisms, and the comparative physiology of calcitonin receptors across mammalian species.
Antho-RFamide is a high-purity, synthetic pentapeptide neuropeptide (pGlu-Gly-Arg-Phe-NH2) originally isolated from marine cnidarians such as the sea anemone Anthopleura elegantissimaand the sea pansy Renilla köllikeri, supplied as a lyophilized white powder for advanced neurobiological and evolutionary research. As a canonical member of the RFamide family of neuropeptides, it features a signature C-terminal Arg-Phe-NH2 (RFamide) motif and an N-terminal pyroglutamate residue, making it a fundamental tool for scientists studying primitive nervous systems, neuromuscular junctions, and G-protein-coupled receptor (GPCR) signaling. Its well-defined sequence and potent bioactivity make it an essential reference standard for academic laboratories, marine biology institutes, and pharmaceutical R&D teams focused on neurophysiology, comparative neuroscience, and the exploration of novel GPCR ligands derived from marine organisms.
CTX IV (6-12) is a synthetic peptide fragment corresponding to the C-terminal telopeptide region of type I collagen, specifically cleaved by the enzyme cathepsin K during bone resorption. This high-purity peptide serves as a critical reference standard for researchers studying bone turnover, osteoporosis, and other metabolic bone diseases, offering reliable calibration for ELISA and mass spectrometry assays.
